Core Viewpoint - Federal Pharmaceutical's subsidiary has received approval for Moxifloxacin Hydrochloride Eye Drops, expanding its ophthalmic product portfolio and reinforcing its position in the ocular anti-infection treatment sector [1] Group 1: Product Approval - The Moxifloxacin Hydrochloride Eye Drops (0.5% in 3ml: 15mg and 0.5% in 5ml: 25mg) have been approved by the National Medical Products Administration of China, with approval numbers H20256128 and H20256129 [1] - Moxifloxacin Hydrochloride is a fourth-generation fluoroquinolone with broad-spectrum antibacterial activity, effective against bacteria causing bacterial conjunctivitis [1] Group 2: Market Position and Strategy - The product is included in the National Medical Insurance Directory (2024 version) as a Class B drug, indicating its accessibility to a wide patient population [1] - The approval is expected to enhance Federal Pharmaceutical's competitive edge in the ocular anti-infection market and contribute to greater returns for the company and its shareholders [1]
联邦制药(03933)：盐酸莫西沙星滴眼液通过国家药品监督管理局上市审批